Thalidomide therapy for cicatricial pemphigoid.
Cicatricial pemphigoid is a chronic, presumed autoimmune, blistering disease of the mucous membranes and occasionally of the skin. The characteristic feature is scarring at the sites of healing. We report the use of thalidomide as a therapeutic agent to control previously resistant disease.
Duong
Daihung Jay
DJ
Department of Neurology, State University of New York at Syracuse, USA.
Moxley
Richard T
RT
Kellman
Robert M
RM
Pincus
Stephanie H
SH
Gaspari
Anthony A
AA
D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007818:Laryngeal Diseases / Q000188:drug therapy*; D008297:Male; D010390:Pemphigoid, Benign Mucous Membrane / Q000188:drug therapy*; D010608:Pharyngeal Diseases / Q000188:drug therapy*; D013792:Thalidomide / Q000008:administration & dosage / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D013792:Thalidomide; D003622:Dapsone